Compare MAMA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | BMEA |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.8M | 96.9M |
| IPO Year | N/A | 2021 |
| Metric | MAMA | BMEA |
|---|---|---|
| Price | $13.53 | $1.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $17.00 | $8.71 |
| AVG Volume (30 Days) | 633.7K | ★ 1.5M |
| Earning Date | 12-08-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.91 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $151,312,000.00 | N/A |
| Revenue This Year | $39.64 | N/A |
| Revenue Next Year | $28.85 | N/A |
| P/E Ratio | $114.25 | ★ N/A |
| Revenue Growth | ★ 29.92 | N/A |
| 52 Week Low | $5.50 | $0.87 |
| 52 Week High | $14.97 | $4.59 |
| Indicator | MAMA | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 45.23 |
| Support Level | $13.24 | $1.30 |
| Resistance Level | $13.90 | $1.34 |
| Average True Range (ATR) | 0.59 | 0.10 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 39.57 | 8.70 |
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.